Panagora Asset Management Inc Jounce Therapeutics, Inc. Transaction History

Panagora Asset Management Inc

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	BUY	$0.9 - $1.85 $23,820 - $48,963	26,467 Added 66.02%	66,554 $123,000
Q4 2022 Feb 13, 2023	SELL	$0.64 - $1.99 $66,688 - $207,358	-104,200 Reduced 72.22%	40,087 $44,000
Q3 2022 Nov 14, 2022	BUY	$2.73 - $4.92 $98,749 - $177,966	36,172 Added 33.46%	144,287 $338,000
Q2 2022 Aug 15, 2022	SELL	$2.8 - $7.67 $42,660 - $116,860	-15,236 Reduced 12.35%	108,115 $328,000
Q1 2022 May 12, 2022	BUY	$6.01 - $8.54 $61,818 - $87,842	10,286 Added 9.1%	123,351 $838,000
Q4 2021 Feb 10, 2022	BUY	$7.11 - $9.64 $52,393 - $71,037	7,369 Added 6.97%	113,065 $944,000
Q3 2021 Nov 10, 2021	BUY	$5.04 - $8.73 $64,658 - $111,997	12,829 Added 13.81%	105,696 $785,000
Q2 2021 Aug 11, 2021	BUY	$6.58 - $10.66 $602,070 - $975,390	91,500 Added 6693.49%	92,867 $631,000
Q4 2020 Feb 10, 2021	SELL	$6.37 - $10.33 $9,746 - $15,804	-1,530 Reduced 52.81%	1,367 $10,000
Q3 2020 Nov 13, 2020	BUY	$4.58 - $10.95 $3,041 - $7,270	664 Added 29.74%	2,897 $24,000
Q2 2020 Aug 12, 2020	SELL	$4.17 - $7.58 $4,182 - $7,602	-1,003 Reduced 31.0%	2,233 $15,000
Q3 2019 Nov 12, 2019	BUY	$3.33 - $4.93 $8,714 - $12,901	2,617 Added 422.78%	3,236 $11,000
Q2 2019 Aug 09, 2019	BUY	$4.3 - $6.73 $2,661 - $4,165	619 New	619 $3,000

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Panagora Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Panagora Asset Management Inc with notifications on news.